We are live on
!
Find out more
RJA
Raymond James & Associates Portfolio holdings
AUM
$164B
1-Year Est. Return
33.91%
This Fund
S&P 500
This Quarter
Est. Return
+7.15%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+221.81%
AUM
$164B
AUM Growth
+$11.8B
(+7.7%)
Cap. Flow
+$2.23B
Cap. Flow
% of AUM
1.36%
Top 10 Holdings %
Top 10 Hldgs %
25.88%
Holding
4,146
New
203
Increased
1,918
Reduced
1,677
Closed
157
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$520M |
| 2 |
UnitedHealth
UNH
|
+$332M |
| 3 |
Analog Devices
ADI
|
+$320M |
| 4 |
Fidelity National Information Services
FIS
|
+$265M |
| 5 |
iShares Core US Aggregate Bond ETF
AGG
|
+$237M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI USA Min Vol Factor ETF
USMV
|
+$516M |
| 2 |
iShares MSCI USA Small-Cap Min Vol Factor ETF
SMMV
|
+$512M |
| 3 |
Cisco
CSCO
|
+$348M |
| 4 |
Apple
AAPL
|
+$162M |
| 5 |
Devon Energy
DVN
|
+$142M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.27% |
| 2 | Financials | 8.92% |
| 3 | Healthcare | 7.98% |
| 4 | Industrials | 6.57% |
| 5 | Consumer Discretionary | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PNST
3876
DELISTED
Pinstripes Holdings, Inc.
PNST
| $27.5K | ﹤0.01% |
35,809
| – | – |
|
|
DHY
3877
Credit Suisse High Yield Credit Fund
DHY
$239M
| $27.2K | ﹤0.01% |
12,000
| – | – |
|
3878
Atomera
ATOM
$187M
| $27K | ﹤0.01% |
10,280
-1,450
| -12% | -$4.52K |
|
3879
Hyliion Holdings
HYLN
$631M
| $26.3K | ﹤0.01% |
10,610
-490
| -4% | -$986 |
|
|
ME
3880
DELISTED
23andMe Holding Co
ME
| $26.3K | ﹤0.01% |
3,781
| – | – |
|
3881
Veru
VERU
$35.8M
| $25.4K | ﹤0.01% |
3,308
+612
| +23% | +$5.28K |
|
|
VZLA
3882
Vizsla Silver
VZLA
$1.12B
| $25K | ﹤0.01% |
+13,000
| New | +$25.1K |
|
3883
Fossil Group
FOSL
$262M
| $24.6K | ﹤0.01% |
21,053
| – | – |
|
|
TE
3884
T1 Energy
TE
$1.16B
| $23.8K | ﹤0.01% |
24,555
| – | – |
|
3885
LanzaTech
LNZA
$60.4M
| $22K | ﹤0.01% |
115
| – | – |
|
|
BCLI
3886
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $21.9K | ﹤0.01% |
6,344
-1,075
| -14% | -$5.07K |
|
3887
Caribou Biosciences
CRBU
$148M
| $21.6K | ﹤0.01% |
11,000
-81,073
| -88% | -$166K |
|
3888
Sol-Gel Technologies
SLGL
$272M
| $21.5K | ﹤0.01% |
3,162
-201
| -6% | -$1.29K |
|
3889
Lineage Cell Therapeutics
LCTX
$267M
| $21.2K | ﹤0.01% |
23,437
-2,289
| -9% | -$2.12K |
|
|
AMRN
3890
Amarin Corp
AMRN
$293M
| $21.2K | ﹤0.01% |
1,689
-55
| -3% | -$730 |
|
3891
Stereotaxis
STXS
$128M
| $21.1K | ﹤0.01% |
10,350
| – | – |
|
|
SOHO
3892
DELISTED
Sotherly Hotels
SOHO
| $20.1K | ﹤0.01% |
16,650
| – | – |
|
|
DNMR
3893
DELISTED
Danimer Scientific, Inc.
DNMR
| $20.1K | ﹤0.01% |
1,105
-46
| -4% | -$803 |
|
3894
CEL-SCI Corp
CVM
$21M
| $20K | ﹤0.01% |
629
| – | – |
|
3895
Solid Power
SLDP
$475M
| $19.2K | ﹤0.01% |
14,250
+500
| +4% | +$791 |
|
3896
Lexicon Pharmaceuticals
LXRX
$1.04B
| $17.1K | ﹤0.01% |
10,912
| – | – |
|
3897
Dawson Geophysical
DWSN
$137M
| $16.7K | ﹤0.01% |
10,593
| – | – |
|
|
IRD
3898
Opus Genetics
IRD
$282M
| $15.4K | ﹤0.01% |
+11,758
| New | +$18.1K |
|
|
LAZR
3899
DELISTED
Luminar Technologies
LAZR
| $14.9K | ﹤0.01% |
1,107
-3,581
| -76% | -$65K |
|
|
CMRX
3900
DELISTED
Chimerix, Inc.
CMRX
| $12.3K | ﹤0.01% |
13,200
-10,000
| -43% | -$8.92K |
|
Similar funds
RJFSA
PI
ECU
EAM
AA
SA
WPL
ECU
Raymond James & Associates's Q3 2024 Portfolio in Review
As of Q3 2024, Raymond James & Associates held 4,146 positions worth $164B, up 7.7% from $152B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Raymond James & Associates's Q3 2024 filing shows 203 new, 1,918 increased, 1,677 reduced and 157 closed positions. Its largest new stake was AllianzIM U.S. Equity Buffer20 Aug ETF: 724,171 shares worth $20.9M. The largest sale was iShares MSCI USA Min Vol Factor ETF, an estimated $516M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Financials and Healthcare.
- Raymond James & Associates's largest Q3 2024 buy was AllianzIM U.S. Equity Buffer20 Aug ETF: 724,171 shares worth $20.9M.
- Raymond James & Associates added most to iShares Core S&P Mid-Cap ETF in Q3 2024, an estimated $520M increase.
- Raymond James & Associates's biggest Q3 2024 reduction was iShares MSCI USA Min Vol Factor ETF, cutting an estimated $516M.
- Raymond James & Associates fully exited Ferguson in Q3 2024, selling an estimated $63.3M.
- Raymond James & Associates's ten largest holdings make up 26% of its $164B portfolio in Q3 2024.
- Raymond James & Associates opened 203 new positions and closed 157 in Q3 2024.
- Raymond James & Associates's portfolio value rose 7.7% quarter-over-quarter to $164B.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.